Tumor apparent diffusion coefficient as an imaging biomarker to predict tumor aggressiveness in patients with estrogen‐receptor‐positive breast cancer

The purpose of this retrospective study was to evaluate whether tumor apparent diffusion coefficient (ADC) was correlated with pathologic biomarkers such as tumor cellularity, Ki67, tumor‐infiltrating lymphocytes (TILs), and peritumoral lymphocytic infiltrate (PLI) in patients with estrogen receptor (ER)‐positive breast cancer.

[1]  A. Goldhirsch,et al.  Is adjuvant chemotherapy useful for women with luminal a breast cancer? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Wolfgang Bogner,et al.  Readout-segmented echo-planar imaging improves the diagnostic performance of diffusion-weighted MR breast examinations at 3.0 T. , 2012, Radiology.

[3]  B. Ross,et al.  Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Wendy B DeMartini,et al.  Improved diagnostic accuracy of breast MRI through combined apparent diffusion coefficients and dynamic contrast‐enhanced kinetics , 2011, Magnetic resonance in medicine.

[5]  Roman Rouzier,et al.  Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response , 2004, Cancer.

[6]  R. Balleine,et al.  Ki67 and proliferation in breast cancer , 2013, Journal of Clinical Pathology.

[7]  Lihua Chen,et al.  The Correlation between Apparent Diffusion Coefficient and Tumor Cellularity in Patients: A Meta-Analysis , 2013, PloS one.

[8]  F. Zeman,et al.  Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry , 2013, Breast Cancer Research and Treatment.

[9]  R. Gelber,et al.  Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Ning-Yu An,et al.  Differentiation of clinically benign and malignant breast lesions using diffusion‐weighted imaging , 2002, Journal of magnetic resonance imaging : JMRI.

[11]  J. Melkko,et al.  Inflammation and prognosis in colorectal cancer. , 2005, European journal of cancer.

[12]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[13]  A. Razek,et al.  Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors , 2010, NMR in biomedicine.

[14]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Dowsett,et al.  Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  S. Mugikura,et al.  Luminal-type breast cancer: correlation of apparent diffusion coefficients with the Ki-67 labeling index. , 2015, Radiology.

[17]  Huiping Li,et al.  Differential impact of tumor-infiltrating immune cells on basal and luminal cells: implications for tumor invasion and metastasis. , 2014, Anticancer research.

[18]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[20]  Wendy B DeMartini,et al.  Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size. , 2010, AJR. American journal of roentgenology.

[21]  Gao Hai-feng,et al.  Proliferation marker Ki-67 in early breast cancer , 2009 .

[22]  M. Iima,et al.  Apparent diffusion coefficient as a potential surrogate marker for Ki‐67 index in mucinous breast carcinoma , 2015, Journal of magnetic resonance imaging : JMRI.

[23]  Qian Wu,et al.  Meta-analysis of quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesions , 2010, BMC Cancer.

[24]  S. Leung,et al.  Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration , 2014, Breast Cancer Research.

[25]  D. McMillan,et al.  The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer , 2012, British Journal of Cancer.

[26]  H. Gilbert Welch,et al.  Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence , 2013 .

[27]  A. Cilotti,et al.  Quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesion , 2007, European Radiology.

[28]  T. Helbich,et al.  Diffusion-weighted MR for differentiation of breast lesions at 3.0 T: how does selection of diffusion protocols affect diagnosis? , 2009, Radiology.

[29]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[30]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Miyati,et al.  The effect of susceptibility of gadolinium contrast media on diffusion-weighted imaging and the apparent diffusion coefficient. , 2008, Academic radiology.

[32]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  W. E. Mesker,et al.  Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854) , 2013, Breast Cancer Research and Treatment.

[34]  L. Bonomo,et al.  Diffusion-weighted imaging in breast cancer: relationship between apparent diffusion coefficient and tumour aggressiveness. , 2010, Clinical radiology.